CALIBRE – Carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis.

Trial Design

A multicentre randomised controlled, open-label, self-evident two-arm trial with internal pilot.


To investigate the clinical and cost-effectiveness of carvedilol versus variceal band ligation in patients with cirrhosis and medium to large oesophageal varices that have not bled.

Sample size

630 – CALIBRE is largest ever Phase III trial in cirrhosis.


NIHR HTA funded – £2.3m. Sponsor is University of Birmingham.


Over 4 years nationally. All acute NHS trusts and health boards in UK are potentially eligible

Primary endpoint

Any variceal bleeding within 1 year of randomisation. Full protocol has been published:

Further information . The CALIBRE website provides full details: